DE3855096D1 - Hemmung von arteriellem thrombotischen Verschluss oder von Thrombo-Embolismus - Google Patents

Hemmung von arteriellem thrombotischen Verschluss oder von Thrombo-Embolismus

Info

Publication number
DE3855096D1
DE3855096D1 DE3855096T DE3855096T DE3855096D1 DE 3855096 D1 DE3855096 D1 DE 3855096D1 DE 3855096 T DE3855096 T DE 3855096T DE 3855096 T DE3855096 T DE 3855096T DE 3855096 D1 DE3855096 D1 DE 3855096D1
Authority
DE
Germany
Prior art keywords
thrombo
embolism
inhibition
thrombotic occlusion
arterial thrombotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3855096T
Other languages
English (en)
Other versions
DE3855096T2 (de
Inventor
John H Griffin
Andras Gruber
Stephen R Hanson
Lawrence A Harker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Clinic and Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22398288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3855096(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scripps Clinic and Research Foundation filed Critical Scripps Clinic and Research Foundation
Application granted granted Critical
Publication of DE3855096D1 publication Critical patent/DE3855096D1/de
Publication of DE3855096T2 publication Critical patent/DE3855096T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • External Artificial Organs (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DE3855096T 1987-11-17 1988-11-16 Hemmung von arteriellem thrombotischen Verschluss oder von Thrombo-Embolismus Expired - Lifetime DE3855096T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/121,702 US5084274A (en) 1987-11-17 1987-11-17 Inhibition of arterial thrombotic occlusion or thromboembolism

Publications (2)

Publication Number Publication Date
DE3855096D1 true DE3855096D1 (de) 1996-04-18
DE3855096T2 DE3855096T2 (de) 1996-07-25

Family

ID=22398288

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3855096T Expired - Lifetime DE3855096T2 (de) 1987-11-17 1988-11-16 Hemmung von arteriellem thrombotischen Verschluss oder von Thrombo-Embolismus

Country Status (11)

Country Link
US (2) US5084274A (de)
EP (1) EP0318201B1 (de)
JP (1) JP2766986B2 (de)
AT (1) ATE135234T1 (de)
CA (1) CA1330036C (de)
DE (1) DE3855096T2 (de)
DK (1) DK175704B1 (de)
ES (1) ES2086301T3 (de)
FI (1) FI104790B (de)
GR (1) GR3020036T3 (de)
NO (1) NO301747B1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
GB8819607D0 (en) * 1988-08-17 1988-09-21 Wellcome Found Novel combination
DE69032029T2 (de) * 1989-12-29 1998-08-20 Zymogenetics, Inc., Seattle, Wash. Hybrides protein c
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
US5571786A (en) * 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
FR2671973A1 (fr) * 1991-01-25 1992-07-31 Fondation Nale Transfusion San Utilisation de la proteine c activee comme agent anti-agregant plaquettaire.
EP0580685B1 (de) * 1991-04-16 1996-01-03 Roche Diagnostics GmbH Pharmazeutische verpackungseinheit enthaltend plasminogenaktivatoren zur mehrfachbolusgabe
AT397615B (de) * 1991-05-14 1994-05-25 Immuno Ag Arzneimittel enthaltend protein c
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
AT402263B (de) * 1991-06-20 1997-03-25 Immuno Ag Pharmazeutische präparation enthaltend eine thrombolytisch wirkende substanz
AT395596B (de) * 1991-06-20 1993-01-25 Immuno Ag Verfahren zur herstellung von aktiviertem protein c
WO1993009807A1 (en) * 1991-11-18 1993-05-27 The Scripps Research Institute Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels
JPH05271098A (ja) * 1992-03-26 1993-10-19 Teijin Ltd 活性化プロテインｃを有効成分とする抗血小板剤
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
US5520912A (en) * 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
JP3043558B2 (ja) * 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
US5510330A (en) * 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
JP4067117B2 (ja) * 1995-06-09 2008-03-26 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 選択性スロンビン抑制剤としてのブラジキニン同族体
TR199902335T2 (xx) * 1997-03-24 2000-01-21 Eli Lilly And Company Vask�ler bozukluklar�n tedavisi.
US6982249B1 (en) 1997-04-23 2006-01-03 The Regents Of The University Of Michigan Bradykinin analogs as selective inhibitors of cell activation
JP2002502421A (ja) * 1997-06-05 2002-01-22 イーライ・リリー・アンド・カンパニー 血栓障害の処置方法
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6953568B1 (en) 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
CN1326357A (zh) 1998-11-23 2001-12-12 伊莱利利公司 治疗镰刀形红细胞贫血病及地中海贫血病的方法
AU2001238034A1 (en) * 2000-02-04 2001-08-14 The Scripps Research Institute Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc)
US7204981B2 (en) 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
US7087578B2 (en) 2000-05-24 2006-08-08 Eli Lilly And Company Formulations and methods for treating hypercoagulable states
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
US20040122354A1 (en) * 2002-09-05 2004-06-24 Semba Charles P. Infusion catheter having an integrated doppler transducer
WO2004056309A2 (en) 2002-12-05 2004-07-08 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US9192657B2 (en) 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
WO2005007820A2 (en) 2003-07-08 2005-01-27 The Scripps Research Institute Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity
WO2006014839A2 (en) * 2004-07-23 2006-02-09 The University Of Rochester Activated protein c inhibits undesirable effects of plasminogen activator in the brain
JP2008531582A (ja) 2005-02-24 2008-08-14 ディフュージョン・ファーマシューティカルズ・エルエルシー トランスカロテノイド、それらの合成、配合、および使用
US7785857B2 (en) * 2006-08-31 2010-08-31 Saint Louis University Protein C variant
CA2668187A1 (en) * 2006-10-31 2008-06-19 The Scripps Research Institute Dosing regimen of activated protein c and variants having reduced anticoagulant activity
EA200970944A1 (ru) 2007-04-13 2010-06-30 Диффьюжн Фармасьютикалз Ллс Применение биполярных транскаротиноидов в качестве предварительного лечения при лечении заболевания периферических сосудов
CA2765697C (en) 2009-06-22 2019-11-12 Diffusion Pharmaceuticals Llc Diffusion enhancing compounds and their use alone or with thrombolytics
EP2575487B1 (de) 2010-06-02 2017-10-18 Diffusion Pharmaceuticals Llc Orale formulierungen aus bipolaren transkarotinoiden
EP2869833B1 (de) 2012-07-04 2018-04-04 ZZ Biotech LLC. Aktiviertes protein c zur behandlung von hautentzündungserkrankungen
WO2015157791A1 (en) 2014-04-16 2015-10-22 The University Of Sydney Treatment of abnormal cutaneous scarring
KR20230014850A (ko) 2016-03-24 2023-01-30 디퓨젼 파마슈티컬즈 엘엘씨 암을 치료하기 위한, 화학 요법 및 방사선 요법과의 양극성 트랜스 카로티노이드의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
JPS6011427A (ja) * 1983-06-29 1985-01-21 Green Cross Corp:The 血栓溶解性蛋白の疾患局所親和性向上方法
GB8319538D0 (en) * 1983-07-20 1983-08-24 Beecham Group Plc Compounds
DE3584902D1 (de) * 1984-02-29 1992-01-30 Asahi Chemical Ind Waessrige loesung eines darin in erhoehter konzentration aufgeloesten gewebe-plasminogen-aktivators und herstellungsverfahren.
AU595173B2 (en) * 1985-01-08 1990-03-29 General Hospital Corporation, The Method and use for site-specific activation of substances
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
CA1341228C (en) * 1985-06-27 2001-05-15 Mark J. Murray Expression of protein c
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4929602A (en) * 1987-11-25 1990-05-29 Scripps Clinic And Research Foundation Method of inhibiting platelet dependent arterial thrombosis

Also Published As

Publication number Publication date
NO301747B1 (no) 1997-12-08
US5084274A (en) 1992-01-28
ATE135234T1 (de) 1996-03-15
FI104790B (fi) 2000-04-14
DK640088D0 (da) 1988-11-16
EP0318201A3 (en) 1990-02-07
DE3855096T2 (de) 1996-07-25
DK640088A (da) 1989-05-18
GR3020036T3 (en) 1996-08-31
EP0318201A2 (de) 1989-05-31
NO885109D0 (no) 1988-11-16
EP0318201B1 (de) 1996-03-13
JPH01238536A (ja) 1989-09-22
CA1330036C (en) 1994-06-07
JP2766986B2 (ja) 1998-06-18
US5350578A (en) 1994-09-27
FI885331A (fi) 1989-05-18
ES2086301T3 (es) 1996-07-01
NO885109L (no) 1989-05-18
DK175704B1 (da) 2005-01-24
FI885331A0 (fi) 1988-11-17

Similar Documents

Publication Publication Date Title
ATE135234T1 (de) Hemmung von arteriellem thrombotischen verschluss oder von thrombo-embolismus
DK463989D0 (da) Farmaceutisk virksom kombination
DE3874798D1 (de) Therapeutisches proteinagens in form von aerosol.
ATE120206T1 (de) Peptide, die die bindung des von-willebrand- faktors inhibieren.
DK0519903T3 (da) Lægemiddel indeholdende aktiveret protein C
ATE104151T1 (de) Trombosebehandlung mit fibrinolytika und prostacyclinen.
DE69110713D1 (de) 7-Oxabicycloheptan-imidazol-prostaglandin-Analoge, verwendbar bei der Behandlung von thrombotischen und vasospastischen Erkrankungen.
DK627687D0 (da) Hirudinvariant
DK50987A (da) Polypeptid med plasminogenaktivatorvirkning
ATE109465T1 (de) 4-aryl-4-piperidine (oder -pyrrolidin- oder - hexahydroazepin-) carbinole und heterocyclische analoga davon.
IT8620922A0 (it) Analoghi di amminoprostaglandine 5,6-epossi-7-ossabicicloeptano sostituite, utili nel trattamentodi trombosi.
NO883963D0 (no) Modifiserte plasminogen-aktivatorer.
DE69023459D1 (de) Behandlung von pulmonarer Disfunktion mit 15-Keto-prostaglandin-Derivaten.
DK213589A (da) Antistoffer mod fibrin og immunogen til brug ved fremstilling deraf
DK301589A (da) Laegemiddel med thrombolytisk virkning
DK0458537T3 (da) Anvendelse af en terapeutisk forbindelse til behandling af bronkitis
MX174250B (es) Composicion con actividad antiagregante de plaqueta util en terapias
DK37988A (da) Fibrinolytisk vaevstype-plasminogenaktivator

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: THE SCRIPPS RESEARCH INSTITUTE, LA JOLLA, CALIF.,

8364 No opposition during term of opposition